```html

Kernicterus (Acute)

What is Kernicterus (Acute)?

Kernicterus, also called acute bilirubin encephalopathy, is a rare but life‑threatening neurological disorder that occurs when excessively high levels of unconjugated (indirect) bilirubin cross the blood‑brain barrier and damage certain brain regions, primarily the basal ganglia, subthalamic nuclei, hippocampus, and cerebellum. In newborns, the condition usually appears within the first week of life, but it can also be seen in older infants and, very rarely, in adults with severe hyperbilirubinemia.

The damage is irreversible once it occurs, leading to permanent motor deficits, hearing loss, gaze abnormalities, and cognitive impairment. Prompt recognition and treatment of rising bilirubin levels are essential to prevent progression to kernicterus.

Common Causes

Acute kernicterus is rarely idiopathic; it is almost always the result of an underlying process that greatly elevates serum unconjugated bilirubin. The most frequent contributors include:

• Hemolytic disease of the newborn (HDN): maternal ABO or Rh incompatibility leading to rapid red‑cell destruction.
• Breast milk jaundice: excess bilirubin production due to enterohepatic circulation and enzymes in breast milk.
• Breast feeding failure: inadequate intake causing dehydration and reduced bilirubin excretion.
• G6PD deficiency: hereditary enzyme defect that predisposes red cells to oxidative damage.
• Crigler‑Najjar syndrome type I: absent UDP‑glucuronosyltransferase activity, producing extreme unconjugated hyperbilirubinemia.
• Sepsis or severe infection: cytokine‑mediated hemolysis and impaired hepatic conjugation.
• Neonatal hypoxia‑ischemia: reduced hepatic perfusion hampers bilirubin metabolism.
• Genetic polymorphisms of UGT1A1 (Gilbert or Rotor syndrome): mild to moderate reductions in bilirubin conjugation that can become critical when combined with other stressors.
• Medications that displace bilirubin from albumin: e.g., sulfonamides, chloramphenicol, some ceftriaxone regimens.
• Prematurity: immature liver enzymes and a higher proportion of fetal hemoglobin increase bilirubin production.

Associated Symptoms

Early bilirubin toxicity may be subtle, but as the level rises the following signs often appear, either alone or together:

• Yellowing of the skin and sclera (jaundice) that progresses despite phototherapy.
• Lethargy or poor feeding.
• High‑pitched cry or abnormal startle reflex.
• Hypotonia or floppiness (especially of the limbs).
• Arching of the back (opisthotonus) as the brain becomes irritated.
• Facial grimacing, especially around the eyes.
• Seizure activity (often focal at first).
• Auditory dysfunction – newborn may not respond to sounds.
• Temperature instability (hypothermia or fever).

When to See a Doctor

Because kernicterus develops quickly once bilirubin crosses a critical threshold, caregivers should seek medical attention immediately if any of the following occur in a newborn or infant:

• Jaundice extending to the abdomen, chest, or arms before 24 hours of age.
• Rapidly worsening yellowing despite phototherapy.
• Newborn is unusually sleepy, difficult to arouse, or not feeding well.
• High‑pitched or inconsolable crying.
• Any sign of muscle weakness, limpness, or abnormal posture.
• Seizure‑like movements, even brief.
• Parents notice the baby does not turn toward spoken words.

In older children or adults with known liver disease, any sudden increase in jaundice, confusion, or loss of consciousness should prompt urgent evaluation.

Diagnosis

Diagnosing acute kernicterus involves a combination of clinical assessment, laboratory testing, and imaging:

1. Laboratory Evaluation

• Total serum bilirubin (TSB): measured in mg/dL; levels > 20 mg/dL in term infants or > 15 mg/dL in preterm infants often warrant aggressive therapy.
• Fractionated bilirubin: differentiates unconjugated from conjugated bilirubin.
• Blood type and Coombs test: to identify hemolytic disease.
• Complete blood count (CBC) and reticulocyte count: assesses hemolysis.
• G6PD assay, liver function tests, and viral serologies: rule out other causes.

2. Neurologic Examination

Clinicians look for the classic triad of lethargy, hypotonia, and abnormal eye movements. The presence of seizures or an abnormal Moro reflex is also significant.

3. Imaging & Neuro‑diagnostic Tools

• Transcranial ultrasound: may show hyperechogenicity in the basal ganglia.
• Brain MRI: the gold standard for detecting bilirubin‑induced injury; T1‑weighted images often reveal hyperintensity in the globus pallidus.
• Auditory brainstem response (ABR): screens for early hearing loss, a frequent sequela.
• EEG: can identify seizure activity or diffuse encephalopathy.

Treatment Options

Management is two‑pronged: rapidly lower serum bilirubin and protect the brain from further injury.

Acute Medical Interventions

• Intensive phototherapy: high‑intensity blue‑light (460 nm) converts unconjugated bilirubin to water‑soluble isomers that can be excreted without conjugation. Double‑surface or fiber‑optic blankets are used for the sickest infants.
• Exchange transfusion: the definitive rescue therapy when bilirubin rises > 25 mg/dL or when neurological signs appear despite maximal phototherapy. Whole blood is exchanged to replace bilirubin‑laden red cells with donor blood.
• Intravenous immunoglobulin (IVIG): may be used in immune‑mediated hemolysis (e.g., ABO incompatibility) to reduce hemolysis and bilirubin production.
• Albumin infusion: in select cases, high‑dose albumin can increase bilirubin‑binding capacity, though evidence is mixed.

Supportive Care

• Maintain adequate hydration and caloric intake (often via nasogastric feeds).
• Correct electrolyte abnormalities and acidosis.
• Monitor for seizures; administer phenobarbital or benzodiazepines as needed.
• Early involvement of neonatal neurology, audiology, and developmental specialists.

Long‑Term Management

Once the acute episode resolves, children may require:

• Physical, occupational, and speech therapy for motor and language delays.
• Regular audiology follow‑up; many require hearing aids or cochlear implants.
• Neurosurgical evaluation for movement disorders (e.g., dystonia).
• Genetic counseling for families with hereditary causes (e.g., Crigler‑Najjar, G6PD).

Prevention Tips

Because kernicterus is almost entirely preventable with early detection of hyperbilirubinemia, the following strategies are recommended:

• Screen all newborns for jaundice before discharge: measure transcutaneous bilirubin or serum TSB.
• Implement the American Academy of Pediatrics (AAP) hyperbilirubinemia risk charts to guide follow‑up timing.
• Encourage early, frequent breastfeeding (≥ 8‑12 times/24 h) to promote stooling and bilirubin excretion.
• Educate parents on “watchful waiting” signs—yellowing that spreads beyond the head or lasts > 24 h.
• For at‑risk infants (e.g., ABO/Rh incompatibility, G6PD deficiency, prematurity), schedule proactive bilirubin checks at 12, 24, and 48 hours of life.
• Avoid drugs that displace bilirubin from albumin unless absolutely necessary; consult neonatology before prescribing.
• Provide phototherapy promptly when bilirubin reaches the treatment threshold defined by age and risk factors.
• In families with a known hereditary conjugation disorder, consider prophylactic phenobarbital or liver transplantation evaluation early in life.

Emergency Warning Signs

Key Take‑Home Points

• Kernicterus (acute) is a preventable brain injury caused by extremely high unconjugated bilirubin.
• Early recognition of rising jaundice, especially in the first week of life, is essential.
• Prompt phototherapy and, when needed, exchange transfusion can stop progression.
• Long‑term neurologic and auditory sequelae are common if treatment is delayed.
• Parental education and systematic newborn screening are the cornerstones of prevention.

---

Sources: Mayo Clinic, American Academy of Pediatrics (AAP) Guidelines for Neonatal Jaundice, CDC – Neonatal Jaundice, National Institutes of Health (NIH) – Liver & Biliary Diseases, Cleveland Clinic, World Health Organization (WHO) – Neonatal Hyperbilirubinemia, and peer‑reviewed articles in The Lancet and Journal of Pediatrics.

```